| Active ingredient (INN) | Ranibizumab |
|---|---|
| Brand names | Byooviz |
| Therapeutic category | Auto-created by Health Canada — Drug Shortages Database scraper |
| Controlled substance | No |
| Marketing-authorisation holders | Samsung Bioepis AU Pty Ltd, Garden House Australia, Novartis Pharmaceuticals Australia Pty Ltd, Midas Pharma GmbH |
| Registrations on file | 5 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| BYOOVIZ ranibizumab | 10 mg | — | 🇦🇺 AU | Samsung Bioepis AU Pty Ltd | Active |
| RANIVIZ ranibizumab | 10 mg | — | 🇦🇺 AU | Garden House Australia | Active |
| LUCENTIS ranibizumab | 2.3 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |
| LUCENTIS ranibizumab | 1.65 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |
| Epruvy | — | — | 🌐 EU | Midas Pharma GmbH | Active |